论文部分内容阅读
乙型肝炎病毒(hepatitis B virus,HBV)复制再活化是指非活动性或已治愈的HBV感染患者血清中HBV DNA再度出现或升高,这一现象常发生在应用化疗药物或者免疫抑制剂治疗期间或之后,然而大多数病例临床症状并不明显,直至发展为活动性肝炎时才被发现.一些随机对照试验建议通过口服抗病毒药物,可有效预防HBV复制再活化的发生.因此,接受化疗药物或者免疫抑制剂治疗的患者均应筛查是否有现症或者既往HBV感染,若乙型肝炎表面抗原阳性,就应该接受抗病毒药物治疗.
Hepatitis B virus (HBV) replication and reactivation refers to the reappearance or increase of HBV DNA in the sera of inactive or cured patients with HBV infection, a phenomenon often occurs in the treatment with chemotherapy drugs or immunosuppressants During or after, however, clinical symptoms in most cases are not obvious until the development of active hepatitis was found.Some randomized controlled trials suggest that oral antiviral drugs can effectively prevent the occurrence of HBV replication and reactivation.Therefore, receiving chemotherapy Patients treated with drugs or immunosuppressive agents should be screened for existing or previous HBV infection, if hepatitis B surface antigen positive, it should be treated with antiviral drugs.